Angiotensin receptor autoantibodies as biomarker for effected usage of angiotensin receptor blockers
AssigneeThe Johns Hopkins University
InventorsJeremy D. Walston, Peter M. Abadir, Alka Jain, Neal Fedarko
Life of this patent
Estimating the term…
Abstract
The invention described herein provides methods for treating a disease or disorder associated with angiotensin receptor signaling in a patient exhibiting elevated levels of ATIR autoantibodies. The invention also provides methods of identifying a patient suffering from a disease or disorder associated with angiotensin receptor signaling that may benefit from treatment with an angiotensin receptor blocker. Patients with elevated levels of ATIR autoantibodies are identified as candidates that particularly benefit from treatment with an angiotensin receptor blocker.
Claims12
A method for treating a disease or disorder associated with angiotensin receptor signaling, the method comprising:
- a) determining a level of angiotensin receptor autoantibodies in a patient sample;
- b) comparing the level of angiotensin receptor autoantibodies in the patient sample to a reference standard comprising between about 5 μg/mL to about 10 μg/mL angiotensin receptor autoantibodies;
- and
- c) if the level of angiotensin receptor autoantibodies present in the patient sample is higher than the reference standard, then administering to the patient an effective amount of an angiotensin receptor blocker.
Dependencies are inferred from the claim text.